These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21691698)

  • 41. Advances in the preparation and synthesis of heparin and related products.
    Baytas SN; Linhardt RJ
    Drug Discov Today; 2020 Dec; 25(12):2095-2109. PubMed ID: 32947045
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
    Glauser BF; Vairo BC; Oliveira SN; Cinelli LP; Pereira MS; Mourão PA
    Thromb Haemost; 2012 Feb; 107(2):302-14. PubMed ID: 22234635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Forensic pharmacovigilance and substandard or counterfeit drugs.
    Labadie J
    Int J Risk Saf Med; 2012; 24(1):37-9. PubMed ID: 22436258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simple fluorescence assay for quantification of OSCS in heparin.
    Lühn S; Schiemann S; Alban S
    Anal Bioanal Chem; 2011 Jan; 399(2):673-80. PubMed ID: 20552175
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A non-hemorrhagic hybrid heparin/heparan sulfate with anticoagulant potential.
    Brito AS; Cavalcante RS; Palhares LC; Hughes AJ; Andrade GP; Yates EA; Nader HB; Lima MA; Chavante SF
    Carbohydr Polym; 2014 Jan; 99():372-8. PubMed ID: 24274520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The tainted heparin story: an update.
    Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
    Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of galactosamine impurities in heparin samples by multivariate regression analysis of their (1)H NMR spectra.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    Anal Bioanal Chem; 2011 Jan; 399(2):635-49. PubMed ID: 20953772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of rat smooth muscle cell adhesion and proliferation by non-anticoagulant heparins.
    Kazi M; Lundmark K; Religa P; Gouda I; Larm O; Ray A; Swedenborg J; Hedin U
    J Cell Physiol; 2002 Dec; 193(3):365-72. PubMed ID: 12384988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial.
    Arsenault KA; Paikin JS; Hirsh J; Dale B; Whitlock RP; Teoh K; Young E; Ginsberg JS; Weitz JI; Eikelboom JW
    J Thorac Cardiovasc Surg; 2012 Oct; 144(4):944-950.e3. PubMed ID: 22743176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The development of an FIA-CD strategy for screening sulfated polysaccharides using antimalarial drugs and related species as probes.
    Stanley FE; Warner AM; Stalcup AM
    Anal Bioanal Chem; 2011 Jan; 399(2):707-16. PubMed ID: 20941481
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Determination of anticoagulant activity of heparin].
    Dalmora SL; Assaf GS; Dalmora ME; Vaucher LC; Vaccari SF
    Rev Hosp Clin Fac Med Sao Paulo; 1991; 46(2):59-62. PubMed ID: 1843369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes.
    Bianchini P; Liverani L; Mascellani G; Parma B
    Semin Thromb Hemost; 1997; 23(1):3-10. PubMed ID: 9156404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Reversal for heparins and new anticoagulant treatments].
    Kortchinsky T; Vigué B; Samama CM
    Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pharmacovigilance in pharmacy practice].
    Duquet N
    J Pharm Belg; 2011 Dec; (4):97-103. PubMed ID: 22299235
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Validation of quantitative polymerase chain reaction methodology for monitoring DNA as a surrogate marker for species material contamination in porcine heparin.
    Auguste C; Dereux S; Rousset M; Anger P
    Anal Bioanal Chem; 2012 Jul; 404(1):43-50. PubMed ID: 22648164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pattern-based recognition of heparin contaminants by an array of self-assembling fluorescent receptors.
    Jagt RB; Gómez-Biagi RF; Nitz M
    Angew Chem Int Ed Engl; 2009; 48(11):1995-7. PubMed ID: 19191358
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bioactive supramolecular hydrogel with controlled dual drug release characteristics.
    Ma D; Tu K; Zhang LM
    Biomacromolecules; 2010 Sep; 11(9):2204-12. PubMed ID: 20831271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.